• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
Right Arrow Button IconLeft Arrow Button IconHome
Right Arrow Button IconPharmaceutical Industry

Pharmaceutical Industry

Page 16 of 100
Many cancer drugs remain unproven 5 years after accelerated approval, a study finds
Health
Many cancer drugs remain unproven 5 years after accelerated approval, a study finds
By Carla K. Johnson and The Associated PressApril 8, 2024
ALS drug will be pulled from US market after study showed patients didn’t benefit
Health
ALS drug will be pulled from US market after study showed patients didn’t benefit
By Matthew Perrone and The Associated PressApril 4, 2024
It’s time for facts in the PBM debate
Commentary
It’s time for facts in the PBM debate
By David JoynerApril 3, 2024
photo portrait of a middle aged man wearing a suit and tie
Newsletters
Johnson & Johnson CIO says employee upskilling is key to transforming health care
By John KellApril 3, 2024
Pharmacies
Health
‘This is an emergency’: Trade group warns nearly a third of all independent pharmacies will go extinct because of a CMS rule
By Maia Anderson, Healthcare Brew and Morning BrewMarch 30, 2024
An out-of-focus person is point to their left and is standing in front of a window with the red and white Walgreens 'W' on it.
Retail
Walgreens’ frail quarter goes beyond the discretionary spending dips afflicting its competitors. It’s ‘just not very good at retailing,’ analyst says
By Sasha RogelbergMarch 29, 2024
The economics of antibiotics are broken and superbugs are on the rise–but a solution inspired by the subscription economy could save millions of lives
Commentary
The economics of antibiotics are broken and superbugs are on the rise–but a solution inspired by the subscription economy could save millions of lives
By Howard DeanMarch 28, 2024
Ozempic maker Novo Nordisk facing pressure as study finds $1,000 appetite suppressant can be made for just $5
Health
Ozempic maker Novo Nordisk facing pressure as study finds $1,000 appetite suppressant can be made for just $5
By Madison Muller, Robert Langreth and BloombergMarch 28, 2024
China woos CEOs of Apple, chipmakers, pharma giants as geopolitical tensions mount: ‘The risk-reward has changed’
Leadership
China woos CEOs of Apple, chipmakers, pharma giants as geopolitical tensions mount: ‘The risk-reward has changed’
By BloombergMarch 23, 2024
Bayer CEO: Corporate bureaucracy belongs in the 19th century. Here’s how we’re fighting it
Commentary
Bayer CEO: Corporate bureaucracy belongs in the 19th century. Here’s how we’re fighting it
By Bill AndersonMarch 21, 2024
After testing new drug compounds that appear to mimic the physical benefits of exercise in rodents, scientists say a pill may someday be able to do the same in humans.
Life
An exercise pill may soon offer the same benefits as a workout, scientists say
By Lindsey LeakeMarch 18, 2024
A man with glasses and a white lab coat stands in front of a glass wall in a medical research facility.
Newsletters
How AI turbocharged the development of a new drug and what it might mean for health care
By Diane BradyMarch 14, 2024
FDA will take a deeper look into the safety and effectiveness of Lilly experimental Alzheimer’s drug
Health
FDA will take a deeper look into the safety and effectiveness of Lilly experimental Alzheimer’s drug
By Tom Murphy, Matthew Perrone and The Associated PressMarch 8, 2024
“Even though health insurance costs are the second-largest line item after payroll, CEOs don’t really understand it or know anything about it,” billionaire entrepreneur and Shark Tank investor Mark Cuban tells Fortune’s Lindsey Leake.
Health
Mark Cuban’s $141K mistake: The Cost Plus Drugs cofounder says CEOs don’t understand health care coverage, and it’s costing them big
By Lindsey LeakeMarch 8, 2024
Photo of Bill Anderson
Health
Bayer CEO compares the state of troubled pharma group to the time he fractured his leg skateboarding: ‘We’re badly broken in 4 places’
By Ryan HoggMarch 6, 2024
1...
  • 14
  • 15
  • 16
  • 17
  • 18
...100
Most Popular
Big Tech
As Big Tech showers employees with perks to win the talent war, Nvidia built a nearly $5 trillion company by making people pay for their own lunchplaceholder alt text
By Marco Quiroz-GutierrezJuly 1, 2026
Success
MacKenzie Scott alone accounted for one-third of America's $19.2 billion in megagifts last yearplaceholder alt text
By Sydney LakeJune 25, 2026
Newsletters
The Supreme Court's birthright citizenship ruling hands the U.S. economy a $7.7 trillion winplaceholder alt text
By Diane BradyJuly 1, 2026
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • World's Most Admired Companies
  • See All Rankings
  • Lists Calendar
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.